-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk has submitted a marketing application for Cagrisema to the US Food and Drug Administration, the first weekly GLP-1 and insulin analogue combination therapy for weight management.

Zhitongcaijing·12/18/2025 13:09:07
Listen to the news
Novo Nordisk has submitted a marketing application for Cagrisema to the US Food and Drug Administration, the first weekly GLP-1 and insulin analogue combination therapy for weight management.